ArticleThe Lancet. Oncology2018

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Jung-Min Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.